مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

303
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

112
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

COMPARISON OF THE EFFECT OF ALEMTUZUMAB VERSUS STANDARD IMMUNE INDUCTION ON EARLY KIDNEY ALLOGRAFT FUNCTION IN SHIRAZ TRANSPLANT CENTER

Pages

  450-156

Abstract

 Background: INDUCTION THERAPY regimens classified as conventional IMMUNOSUPPRESSIVE AGENTS and lower doses of conventional agents combined with antibodies against T-cell antigens have been purposed to prevent acute rejection after renal transplantation. Various induction agents with different doses and durations have been suggested based on the risk profile of patients.Objective: To assess the acute rejection rate (total rate and based on the type of INDUCTION THERAPY regimen) during the first year after KIDNEY TRANSPLANTATION, the type of acute rejection based on Banff classification and to determine the associations between rate of acute rejection, type of the rejection and INDUCTION THERAPY regimen.Methods: 249 kidney transplant candidates were divided into two groups-low-risk patients (n=208) who received conventional IMMUNOSUPPRESSIVE AGENTS, and high-risk patients (n=41) who received ALEMTUZUMAB-and followed for one year to detect acute rejection first diagnosed clinically, and confirmed by percutaneous kidney biopsy based on Banff criteria.Results: The total incidence of acute rejection was 19.6% (20.7% of the low-risk and 14.4% of the high-risk patients). The most prevalent types of the acute rejection in patients treated with conventional IMMUNOSUPPRESSIVE AGENTS and patients received ALEMTUZUMAB as INDUCTION THERAPY were grade IB and grade IA, respectively. The incidence of acute rejection among recipients received a kidney from a deceased donor was 20.6% and grade IA was the most prevalent type (6.9%) whereas the most prevalent grade of acute rejection in patients who received living donor grafts was IB (8.3%).Conclusion: Despite the expected greater risk for acute rejection among high-risk patients, no significant difference was observed between low- and high-risk patients, which may be justified by the greater efficacy of ALEMTUZUMAB compared with standard triple INDUCTION THERAPY in reducing the rate of acute rejection.

Cites

  • No record.
  • References

  • No record.
  • Cite

    APA: Copy

    KHALAFI NEZHAD, A., SAGHEB, M.M., AMIRMOEZI, FATEMEH, JOWKAR, Z., & DEHGHANIAN, A.R.. (2015). COMPARISON OF THE EFFECT OF ALEMTUZUMAB VERSUS STANDARD IMMUNE INDUCTION ON EARLY KIDNEY ALLOGRAFT FUNCTION IN SHIRAZ TRANSPLANT CENTER. INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE, 6(4), 450-156. SID. https://sid.ir/paper/327548/en

    Vancouver: Copy

    KHALAFI NEZHAD A., SAGHEB M.M., AMIRMOEZI FATEMEH, JOWKAR Z., DEHGHANIAN A.R.. COMPARISON OF THE EFFECT OF ALEMTUZUMAB VERSUS STANDARD IMMUNE INDUCTION ON EARLY KIDNEY ALLOGRAFT FUNCTION IN SHIRAZ TRANSPLANT CENTER. INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE[Internet]. 2015;6(4):450-156. Available from: https://sid.ir/paper/327548/en

    IEEE: Copy

    A. KHALAFI NEZHAD, M.M. SAGHEB, FATEMEH AMIRMOEZI, Z. JOWKAR, and A.R. DEHGHANIAN, “COMPARISON OF THE EFFECT OF ALEMTUZUMAB VERSUS STANDARD IMMUNE INDUCTION ON EARLY KIDNEY ALLOGRAFT FUNCTION IN SHIRAZ TRANSPLANT CENTER,” INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE, vol. 6, no. 4, pp. 450–156, 2015, [Online]. Available: https://sid.ir/paper/327548/en

    Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button